This article is available online at http://dmd.aspetjournals.org ABSTRACT:In this study, we investigated the possible involvement of acylCoA, reactive intermediary metabolites of 2-arylpropionic acids (profens), in protein adduct formation in rat liver homogenate and in human serum albumin ( 2-Arylpropionic acids (profens) are a commonly used class of nonsteroidal anti-inflammatory drugs, widely prescribed as analgesic, antipyretic, and anti-inflammatory agents. Conjugation with glucuronic acid is a major route for the biotransformation and elimination of profen drugs, such as ibuprofen, carprofen, fenoprofen, and naproxen (Spahn-Langguth et al., 1997). Studies have shown that these acyl-linked glucuronides are chemically reactive species that undergo hydrolysis to regenerate the pharmacologically active parent drug and that also undergo intramolecular acyl migration to yield -glucuronidase-resistant isomers (Spahn-Langguth and Benet, 1992;Spahn-Langguth et al., 1997;. More importantly, these electrophilic metabolites have been shown to bind covalently to serum albumins in vitro and to plasma and tissue proteins in vivo (Spahn-Langguth and Benet, 1992;; and, therefore, metabolic activation of profen drugs by acyl glucuronidation has been proposed as a metabolic route to mediate the idiosyncratic liver toxicity associated with the use of profen drugs (Boelsterli et al., 1995).Another metabolic route of profen drugs is the acyl-CoA thioester pathway, recently recognized also as yielding reactive metabolites of acidic drugs. Sallustio et al. (2000) demonstrated that covalent binding of nafenopin to human liver proteins is directly associated with formation of a nafenopin acyl-CoA thioester intermediate. A number of studies on protein fatty acylation have shown that endogenous acyl-CoAs, including palmitoyl-CoA and arachidonoyl-CoA, can react nonenzymatically with sulfhydryl groups on proteins and peptides in vitro in a time-and concentration-dependent fashion (Bharadwaj and Bizzozero, 1995;Duncan and Gilman, 1996). Our recent studies with 2-phenylpropionic acid (2-PPA 3 ) demonstrated that 2-phenylpropionyl-S-acyl-CoA (2-PPA-CoA) was able to acylate glutathione sulfhydryl to form 2-PPA-S-acyl-glutathione at a rate that was approximately 70-fold more rapid than the similar reactions with 2-PPA-1-O-acyl glucuronides . The present study was designed to examine the covalent binding of 2-PPA-CoA to human serum albumin and rat liver homogenate in vitro. 2-PPA was chosen because it is the simplest congener of profen drugs and is capable of forming 2-PPA-CoA, as inferred from the unidirectional chiral inversion of 2-PPA in vivo (Fournel and Caldwell, 1986). Results from these in vitro studies strongly suggest that acyl-CoA thioesters of profen drugs are chemically reactive electrophiles and are able to bind covalently to tissue proteins in vitro, which may, therefore, contribute significantly to covalent adduct formation of profen drugs in vivo, in addition to acyl glucuronides. Materials and Methods Materials. (R)-(Ϫ)-
Context/objective: Only sparse evidence exists regarding the effectiveness of oral alendronate (ALN) in the prevention of heterotopic ossification (HO) in patients with spinal cord injury (SCI). The objective of this study is to investigate the protective effect of oral ALN intake on the appearance of HO in patients with SCI. Study design: Retrospective database review. Setting: A Spinal Cord Unit at a Rehabilitation Hospital. Participants: Two hundred and ninety-nine patients with SCI during acute inpatient rehabilitation. Interventions: Administration of oral ALN. Outcome measures: The incidence of HO during rehabilitation was compared between patients with SCI receiving oral ALN (n = 125) and patients with SCI not receiving oral ALN (n = 174). The association between HO and/or ALN intake with HO risk factors and biochemical markers of bone metabolism were also explored. Results: HO developed in 19 male patients (6.35%), however there was no significant difference in the incidence of HO in patients receiving oral ALN or not. The mean odds ratio of not developing versus developing HO given ALN exposure was 0.8. Significant correlation was found between abnormal serum alkaline phosphatase (ALP) levels and HO appearance (P < 0.001) as well as normal serum ALP and ALN intake (P < 0.05). Conclusion: Even though there was no direct prevention of HO in patients with SCI by oral ALN intake, abnormal serum ALP was found more frequently in patients with HO development and without oral ALN intake. This evidence could suggest that ALN may play a role in preventing HO, especially in patients with acute SCI with increasing levels of serum ALP.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.